Cell viability of CRC cell lines was assessed in a variety of different treatment conditions in the presence or absence of PBMCs so that drug-specific effects on cell viability can be compared with any additional cytotoxicity caused by PBMCs or PD-1 inhibitor. The gene discussed is PDCD1; the disease is colorectal carcinoma.